On Monday, Adobe Systems Incorporated (NASDAQ:ADBE)’s shares inclined 0.99% to $79.87.
Adobe Systems Incorporated (ADBE) released its annual Digital Index Travel Report, which reveals the best times to book airfare and hotels, top destinations, total online travel spend, consumer buying behaviors across devices and more. The report analyzed more than 15 billion visits across major U.S. travel, airline and hotel sites between 2013 and 2015 and more than three million social media mentions. Consumers are predictable to spend $65 billion online on travel between Memorial Day and Labor Day, seven percent more than in 2014. Twenty percent of travel bookings are now coming from smartphones and tablets, over six percent more than last year. The analysis also shows that Washington D.C. tops the list of U.S. travel destinations followed by Los Angeles, New York, Las Vegas and San Francisco.
Adobe’s annual travel report provides the most comprehensive set of travel insights in the industry and is based on aggregated and anonymous data from Adobe Marketing Cloud. Pricing details are based on booking transactions, which ensures highly accurate predictions. The report analyzed traffic and sales across major U.S. travel, airline and hotel sites counting seven of the top ten airlines and eight of the top ten hotel chains. Adobe also conducted a complementary survey of 1,000 U.S. consumers who plan to travel this summer.
Adobe Systems Incorporated operates as a diversified software company worldwide. It operates in three segments: Digital Media, Digital Marketing, and Print and Publishing. The Digital Media segment provides tools and solutions that enable individuals, small and medium businesses, and enterprises to create, publish, promote, and monetize their digital content.
Synthetic Biologics Inc (NYSEMKT:SYN)’s shares gained 14.74% to $2.18.
Synthetic Biologics Inc (SYN) declared Klaus Gottlieb, MD, FACG, has joined the Company as Vice President, Clinical & Regulatory Affairs, effective June 22, 2015. Dr. Gottlieb’s appointment expands the clinical and regulatory leadership team as the Company moves into Phase 2 clinical trials for its irritable bowel syndrome with constipation (IBS-C) and C. difficile programs. He will report to Joseph Sliman, MD, MPH, Synthetic Biologics’ Senior Vice President, Clinical & Regulatory Affairs.
Dr. Gottlieb is an practiced board-certified internist and gastroenterologist with a strong clinical science, business and drug development background. He has led cross-functional teams in a variety of settings in industry, academia, private practice and with the FDA. He joins Synthetic Biologics after serving as Senior Medical Director-Therapeutic Strategy Lead Gastroenterology of Quintiles, a Fortune 500 company and the world’s largest provider of biopharmaceutical development and commercial outsourcing services. At Quintiles, Dr. Gottlieb served as Global Medical Advisor for three separate large Phase 3 inflammatory bowel disease (IBD) trials and offered noteworthyinput on the shaping, design and evaluation of numerous IBD and other gastrointestinal (GI) clinical trials throughout all stages of development programs. Prior to joining Quintiles in 2013, he was with the FDA in Silver Spring, MD as a Senior Clinical Reviewer for the Division of Gastroenterology and Inborn Errors Products. Formerly, Dr. Gottlieb spent 11 years at Sacred Heart Medical Center, a 500-bed full service hospital in Spokane, WA.
Synthetics Biologics, Inc., a clinical-stage biotechnology company, develops pathogen-specific therapies for serious infections and diseases with a focus on protecting the microbiome.
At the end of Monday’s trade, Anthem Inc (NYSE:ANTM)‘s shares surged 0.13% to $168.07.
The Anthem Inc (ANTM) cancer treatment pathways are based on the medical evidence that analyzes outcomes related to clinical benefit, both survival and quality of life, toxicity, strength of national guideline recommendations and lastly, costs are considered when clinical outcomes among therapies are equivalent. They are reviewed by external advisors that comprise of about dozen geographically diverse physicians who are actively treating patients and work in academic and community oncology groups and have specific interest in quality of care.
Since the first rollout of the program in Indiana, Kentucky, Missouri, Ohio, Wisconsin, and Georgia in July, 2014, the program has expanded to comprise other cancers, such as ovarian, pancreatic, leukemia, lymphoma, melanoma, myeloma, prostate and cancers that impact the central nervous system. By July 1, the program will be implemented for patients and providers in 13 states.
Oncology practices provide clinical data on biomarkers, performance status and planned treatment into the Cancer Care Quality Program platform, administered and developed in partnership with AIM Specialty Health. Oncologists who take part in the program and choose one of the possible cancer treatment pathways based on the latest medical evidence are eligible to receive an additional $350 payment for treatment planning and care coordination for each month the patient is in active therapy. Those who do not choose a pathway, in addition to those who do, continue to be reimbursed for drug purchase and administration as they have formerly.
Anthem, Inc., through its auxiliaries, operates as a health benefits company in the United States. It operates through three segments: Commercial and Specialty Business, Government Business, and Other.
Kratos Defense & Security Solutions, Inc (NASDAQ:KTOS), ended its Monday’s trading session with -1.50% loss, and closed at $5.90.
Kratos Defense & Security Solutions, Inc (KTOS) a leading National Security Solutions provider, declared recently that its Defense & Rocket Support Services (DRSS) Division has recently been awarded a $4.5 million, two-year contract in support of certain directed energy programs for a United States Government customer. DRSS is a leading provider of products, systems, solutions and support services for many of the United States’ leading and disruptive technology programs, counting electromagnetic railgun, directed energy and laser systems, hypersonics and ballistic missile defense target systems. Due to customer related and other considerations, no additional information is being offered related to this new contract award.
DRSS is a leading provider of high technology products and solutions for planned national security programs and initiatives, counting disruptive railgun, hypersonic vehicle, directed energy weapon and ballistic missile defense target programs and missile and combat system upgrade and support.
Kratos Defense & Security Solutions, Inc. provides mission critical products, solutions, and services primarily for the United States Government. The company operates through three segments, Kratos Government Solutions (KGS), Unmanned Systems, and Public Safety & Security (PSS). The Kratos Government Solutions segment offers command, control, communications, computing, combat systems, intelligence, surveillance, and reconnaissance (C5ISR) products; solutions; and services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
